News
In addition to lowering its price target from $105 to $64 to market perform, BMO lowered its rating on Novo Nordisk’s shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback